Bio-ADM, the very first blood biomarker capable to diagnose when blood vessels become leaky (endothelial dysfunction), is set to make a rapid carrier at intensive care units (ICUs) and emergency departments (EDs) of hospitals. Data from pilot clinical routine testing presented at the 2nd Scientific Symposium on Endothelial Disruption (18. December 2018) in Berlin impressively confirmed results from previous tests on 30,000 patients with acute heart failure (AHF) and severe sepsis indicating that bio-ADM testing improves medical decision making to prevent mortality, organ damage and rehospitalisation. An automated point-of-care (POC) test measuring bio-ADM both as a biomarker and as a companion diagnostic to a therapeutic antibody (adrecizumab) that repairs endothelial dysfunction, will be launched by H1/2019 by Sphingotec GmbH. However, bio-ADM is just the first representative of a full pipeline of diagnostic blood proteins reflecting disturbed signalling pathways underlying disorders of unmet medical need.
VTT turn waste into biofuels and chemicals
Latest NewsResearchers at VTT Technical Research Centre of Finland Ltd have presented a new gasification-based technique to turn forest industry byproducts into transport fuels and chemicals.
Tissue specific tumour transition needs few cells
Latest NewsGerman researchers have modeled when cellular alterations inevitably lead to the development of cancer. The transition is tissue-specific and needs only a few cells.
Highest manufacturing standard: First Line
BackgroundDatwyler Sealing Solutions is a leading industrial supplier and a key player in the global health care world. Our unique product range includes the most advanced elastomer formulations, coatings, aluminum seals, and processing technologies. These are based on a broad spectrum of experience in the healthcare industry. To ensure the highest quality in our broad product portfolio, we have implemented the most advanced manufacturing standard.
Drug dissociates metastasis precursors in blood
Latest NewsA team of Swiss researchers has identified Na+/K+-ATPase blockers as candidate drugs capable to prevent formation of metastases. In blood, the repurposed drugs identified in a screening dissociated clusters of circulating tumour cells (CTCs), forerunners of metastases.
Policymakers take no action after ECJ mutagenesis ruling
Latest NewsIn summer the European Court of Justice (ECJ) ruled that crops created by biological mutagenesis techniques fall under EU GMO legislation. Germanys government and the European Parliament see no need to take action.
Immuno-Oncology experts to join Protagen AG board
AppointmentsProtagen AG, a precision medicine specialist at the forefront of immuno-profiling, announced today the appointment of Immuno-Oncology experts PD Dr. Jessica Hassel (National Center for Tumor Diseases, Heidelberg, Germany) and Dr. Aurélien Marabelle (Gustave Roussy, Paris, France) to its Scientific Advisory Board.
Sandoz antiinfectives partner Ares Genetics gets fund
Latest NewsJust in mid-December, antibiotic resistance detection expert Ares Genetics (Vienna, Austria) inked an agreement with Sandoz to use its pathogenome database and bio-IT know-how to develop repurposed and novel antiinfectives that help fight antimicrobial resistance (AMR). Now, the company baged another financing to expand its diagnostic capabilities.
AI provides face read-out of genetic diseases
Latest NewsExperts in artificial intelligence (AI) have created another problem for bioethicists and data protection specialists: their algorithm has learned to identify people with rare genetic syndromes from facial images.
Immunocore appoints Bahija Jallal as CEO
AppointmentsImmunocore has appointed Bahija Jallal as Chief Executive Officer and Director of the Board.
Endothelial disruption: From bench to bedside
BackgroundBio-ADM, the very first blood biomarker capable to diagnose when blood vessels become leaky (endothelial dysfunction), is set to make a rapid carrier at intensive care units (ICUs) and emergency departments (EDs) of hospitals. Data from pilot clinical routine testing presented at the 2nd Scientific Symposium on Endothelial Disruption (18. December 2018) in Berlin impressively confirmed results from previous tests on 30,000 patients with acute heart failure (AHF) and severe sepsis indicating that bio-ADM testing improves medical decision making to prevent mortality, organ damage and rehospitalisation. An automated point-of-care (POC) test measuring bio-ADM both as a biomarker and as a companion diagnostic to a therapeutic antibody (adrecizumab) that repairs endothelial dysfunction, will be launched by H1/2019 by Sphingotec GmbH. However, bio-ADM is just the first representative of a full pipeline of diagnostic blood proteins reflecting disturbed signalling pathways underlying disorders of unmet medical need.